Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1 study of 225Ac-PSMA-Trillium in metastatic castration-resistant prostate cancer
jRCT2031260269Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of BAY 3563254 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Bayer. Primary endpoints: Incidence and severity of treatment-emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) in dose escalation, Recommended safe and active dose (RSAD) based on incidence of dose-limiting toxicities (DLTs) and preliminary activity (ORR, PSA50) and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
BAY 3563254
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031260269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260269.